Q-omics provides the consensus-scored CDK6 profile across patient tissues and cancer cell-line models. CDK6 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDK6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CDK6 RNA expression shows 20,445 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where CDK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK6 survival associations across molecular data types. CDK6 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK6 RNA expression–survival associations across cancer types. High CDK6 expression shows unfavorable associations in MESO, ACC, BLCA, PAAD and LGG, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CDK6 RNA expression.
This table summarizes CDK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK6 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, LUSC and COAD. The HNSC box plot shows higher CDK6 RNA expression in tumor versus normal tissue (log2 FC = +1.981, t-test p < 0.001).
This table shows molecular features associated with CDK6 in patient tissues and cancer cell lines. In patient samples, CDK6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
